AltheRx.com

AltheRx Pharmaceuticals

AltheRx HOMEABOUT AltheRxAltheRx DEVELOPMENT PROGRAMNEWSROOMCAREERS AT AltheRxCONTACT AltheRx

   
   
   
 

 
Overview
Management
Board of Directors
Scientific Advisors
Business Development

 

 

 

The mission of AltheRx™ is to improve patients’ lives by potentially transforming the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS).

AltheRx Pharmaceuticals is a privately held, clinical development company focused on advancing best-in-class compounds with high promise in large unmet markets. The Company is focused on clinical development and optimizing commercialization through partnerships. The AltheRx name is a derivative of the name of the Greek goddess of healing, Althea.

The Company’s lead product, solabegron, is a highly differentiated novel compound being investigated for OAB and IBS, conditions that affect the quality of life for more than 90 million Americans − a number that will grow significantly as the population ages. solabegron was discovered and first developed by GlaxoSmithKline and acquired by AltheRx in March 2011.

The company’s co-founders have decades of leadership experience in the pharmaceutical and biotechnology industries.

AltheRx was formed in 2010.